Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

68.87USD
8:01pm GMT
Change (% chg)

$-0.19 (-0.28%)
Prev Close
$69.06
Open
$69.35
Day's High
$69.69
Day's Low
$68.26
Volume
556,184
Avg. Vol
1,655,769
52-wk High
$74.15
52-wk Low
$54.32

Latest Key Developments (Source: Significant Developments)

NY A.G. Underwood Announces Settlement With Abbott Labs
Friday, 9 Nov 2018 

Nov 9 (Reuters) - New York Attorney General Barbara Underwood::SETTLEMENT RESOLVING INVESTIGATION INTO ABBOTT LABORATORIES OVER "MISLEADING" MARKETING SURVEYS COMPANY SENT.SAYS SETTLEMENT REQUIRES ABBOTT TO ACCURATELY DISCLOSE PURPOSE FOR WHICH SURVEY INFORMATION IS SOUGHT.SETTLEMENT ALSO REQUIRES ABBOTT TO PAY $50,000 IN COSTS.  Full Article

Abbott's Heartmate 3 Heart Pump Now FDA Approved For Advanced Heart Failure Patients Not Eligible For Heart Transplant
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Abbott Laboratories ::ABBOTT'S HEARTMATE 3 HEART PUMP NOW FDA APPROVED FOR ADVANCED HEART FAILURE PATIENTS NOT ELIGIBLE FOR A HEART TRANSPLANT.  Full Article

Abbott Labs Sees FY 2018 Organic Sales Growth Of About 7 Pct
Wednesday, 17 Oct 2018 

Oct 17 (Reuters) - Abbott Laboratories ::SEES FY 2018 ORGANIC SALES GROWTH OF ABOUT 7 PERCENT - CONF. CALL.SEES Q4 ORGANIC SALES GROWTH OF MID-TO-HIGH SINGLE DIGITS.  Full Article

Abbott Laboratories Reports Q3 Adjusted EPS $0.75 From Continuing Operations
Wednesday, 17 Oct 2018 

Oct 17 (Reuters) - Abbott Laboratories ::ABBOTT REPORTS THIRD-QUARTER 2018 RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.75 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.Q3 GAAP EARNINGS PER SHARE $0.31 FROM CONTINUING OPERATIONS.Q3 EARNINGS PER SHARE VIEW $0.75 -- THOMSON REUTERS I/B/E/S.SEES Q4 ADJUSTED EARNINGS PER SHARE $0.80 TO $0.82 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $2.87 TO $2.89 FROM CONTINUING OPERATIONS.SEES Q4 2018 GAAP EARNINGS PER SHARE $0.39 TO $0.41 FROM CONTINUING OPERATIONS.THIRD-QUARTER REPORTED SALES GROWTH OF 12.1 PERCENT; ORGANIC SALES GROWTH OF 7.8 PERCENT.THIRD-QUARTER WORLDWIDE SALES OF $7.7 BILLION.QTRLY TOTAL PEDIATRIC SALES $1,039 MILLION VERSUS $975 MILLION REPORTED LAST YEAR.QTRLY TOTAL NUTRITION SALES $1,838 MILLION VERSUS $1,768 MILLION REPORTED LAST YEAR.QTRLY TOTAL DIAGNOSTICS SALES $1,824 MILLION VERSUS $1,279 MILLION REPORTED LAST YEAR."IN SPITE OF INCREASING CURRENCY HEADWINDS, WE'RE WELL-POSITIONED TO ACHIEVE UPPER END OF OUR INITIAL FULL-YEAR GUIDANCE".SEES FULL-YEAR 2018 DILUTED EPS GUIDANCE RANGE FROM CONTINUING OPERATIONS ON A GAAP BASIS $1.33 TO $1.35.Q3 REVENUE VIEW $7.65 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $2.89 -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $0.82 -- THOMSON REUTERS I/B/E/S.NARROWED ITS FULL-YEAR 2018 DILUTED EPS GUIDANCE RANGE FROM CONTINUING OPERATIONS ON A GAAP BASIS TO $1.33 TO $1.35.  Full Article

Abbott's Freestyle Libre 2 Secures CE Mark For Use In Europe
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Abbott Laboratories ::ABBOTT′S FREESTYLE® LIBRE 2, WITH OPTIONAL REAL-TIME ALARMS, SECURES CE MARK FOR USE IN EUROPE.  Full Article

Abbott Receives CE Mark For First Troponin Test To Help Predict The Chance Of Heart Attack
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Abbott Laboratories ::ABBOTT RECEIVES CE MARK FOR FIRST TROPONIN TEST TO HELP PREDICT THE CHANCE OF HEART ATTACK IN APPARENTLY HEALTHY ADULTS POTENTIALLY MONTHS TO YEARS IN ADVANCE.  Full Article

One-Year Results From Real-World Study Showed Abbott's Portico Transcatheter Aortic Valve Safely And Successfully Reduced Severe Aortic Stenosis
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Abbott Laboratories ::ONE-YEAR RESULTS FROM REAL-WORLD STUDY SHOWED ABBOTT'S PORTICO TRANSCATHETER AORTIC VALVE SAFELY AND SUCCESSFULLY REDUCED SEVERE AORTIC STENOSIS.ABBOTT-AT 1 YEAR, IMPLANTATION WITH PORTICO VALVE WAS SAFE,ASSOCIATED WITH LOW RATES OF STROKE, DEATH,LEAKS BETWEEN PATIENTS' NATURAL HEART TISSUE & PORTICO VALVE.  Full Article

Abbott Says COAPT Study Of Mitraclip Meets Primary Safety And Efficacy Endpoints And All Secondary Endpoints
Sunday, 23 Sep 2018 

Sept 23 (Reuters) - Abbott Laboratories ::LANDMARK STUDY SHOWS TREATMENT WITH ABBOTT'S MITRACLIP® IS SUPERIOR TO MEDICAL THERAPY FOR ADVANCED HEART FAILURE PATIENTS WITH SIGNIFICANT SECONDARY MITRAL REGURGITATION.COAPT STUDY MET BOTH PRIMARY SAFETY AND EFFICACY ENDPOINTS AND ALL SECONDARY ENDPOINTS.  Full Article

Abbott's Freestyle Libre 14 Day Flash System Approved In U.S.
Friday, 27 Jul 2018 

July 27 (Reuters) - Abbott Laboratories ::ABBOTT'S FREESTYLE® LIBRE 14 DAY FLASH GLUCOSE MONITORING SYSTEM NOW APPROVED IN U.S..ABBOTT -FREESTYLE LIBRE 14 DAY SYSTEM TO BE AVAILABLE VIA PRESCRIPTION IN COMING MONTHS AT PARTICIPATING PHARMACIES, DMES IN U.S..  Full Article

Abbott Begins U.S. Pivotal Trial For Tendyne Mitral Valve Replacement System
Thursday, 26 Jul 2018 

July 26 (Reuters) - Abbott Laboratories ::ABBOTT BEGINS U.S. PIVOTAL TRIAL FOR THE TENDYNE MITRAL VALVE REPLACEMENT SYSTEM TO TREAT PATIENTS WITH HEART VALVE DISEASE.  Full Article

CORRECTED-FOCUS-U.S. regulators snip red tape for medical devices to curb opioid crisis

Nov 9 Laura Perryman expected her medical company, Stimwave Technologies Inc, would have to wait several years for its painkilling device to win U.S. approval as a treatment for chronic migraines.